---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-23-000150"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2023-11-28T23:59:59+00:00"
generated_at: "2026-06-07T21:05:57.164065+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Immunovant reports positive IMVT-1402 600 mg Phase 1 data: 74% IgG reduction, placebo-like albumin/LDL-C

## Summary
- Four weekly 600 mg SC doses of IMVT-1402 reduced total IgG by mean 74%, similar to batoclimab's 76% at 680 mg.
- No significant changes in serum albumin or LDL-C at Day 29 (p>0.05), consistent with placebo-like profile.
- All doses well tolerated; only mild or moderate treatment-emergent adverse events observed.
- Company expects ~80% steady-state IgG reduction with continued weekly 600 mg dosing after 6-8 weeks.
- Immunovant says profile supports broad portfolio of first-in-class and best-in-class FcRn indications.

## SEC filing metadata
- accession: 0001764013-23-000150
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2023-11-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000150/0001764013-23-000150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401323000150/imvt-20231128.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-23-000150
- JSON: https://secwatch.observer/filing/0001764013-23-000150.json
- Plain text: https://secwatch.observer/filing/0001764013-23-000150.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.